O-linked β-N-acetylglucosamine transferase directs cell proliferation in idiopathic pulmonary arterial hypertension

Circulation

Volumn 131, Issue 14, 2015, Pages 1260-1268

  Barnes, Jarrod W ^a   Tian, Liping ^a   Heresi, Gustavo A ^a   Farver, Carol F ^a   Asosingh, Kewal ^a   Comhair, Suzy A A ^a   Aulak, Kulwant S ^a   Dweik, Raed A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Biosynthetic pathways; Hexosamines; Host cell factor C1; Pulmonary hypertension; Smooth muscle; UDP N acetylglucosamine peptide beta N acetylglucosaminyltransferase

Indexed keywords

HEXOSAMINE; HOST CELL FACTOR 1; HYDROLASE; O LINKED BETA N ACETYLGLUCOSAMINE HYDROLASE; O LINKED BETA N ACETYLGLUCOSAMINE TRANSFERASE; TRANSCRIPTION FACTOR; TRANSFERASE; UNCLASSIFIED DRUG; ALLOXAN; GLUCOSE; HCFC1 PROTEIN, HUMAN; HOST CELL FACTOR C1; N ACETYLGLUCOSAMINYLTRANSFERASE; UDP-N-ACETYLGLUCOSAMINE-PEPTIDE BETA-N-ACETYLGLUCOSAMINYLTRANSFERASE;

ADULT; ARTICLE; BIOSYNTHESIS; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLUCOSE METABOLISM; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG; MALE; PRIORITY JOURNAL; PULMONARY ARTERY SMOOTH MUSCLE CELL; PULMONARY HYPERTENSION; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL DIVISION; DISEASE COURSE; ENZYMOLOGY; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HOSPITALIZATION; LUNG TRANSPLANTATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROTEIN PROCESSING; PULMONARY ARTERY; SMOOTH MUSCLE CELL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTILIZATION; VASCULAR SMOOTH MUSCLE; YOUNG ADULT;

ADULT; ALLOXAN; CELL DIVISION; CELLS, CULTURED; DISEASE PROGRESSION; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; GLUCOSE; GLYCOSYLATION; HEXOSAMINES; HOSPITALIZATION; HOST CELL FACTOR C1; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; N-ACETYLGLUCOSAMINYLTRANSFERASES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PULMONARY ARTERY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929335104     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.013878     Document Type: Article

References (55)

1. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J. 2012;40:1555-1565. doi: 10.1183/09031936.00046612.
2. Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res. 2014;115:148-164. doi: 10.1161/CIRCRESAHA.115.301130.
3. Tuder RM, Archer SL, Dorfmüller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D4-D12. doi: 10.1016/j.jacc.2013.10.025.
4. Austin ED, Loyd JE. The genetics of pulmonary arterial hypertension. Circ Res. 2014;115:189-202. doi: 10.1161/CIRCRESAHA.115.303404.
5. Marsboom G, Wietholt C, Haney CR, Toth PT, Ryan JJ, Morrow E, Thenappan T, Bache-Wiig P, Piao L, Paul J, Chen CT, Archer SL. Lung (1)(8)F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2012;185:670-679.
6. Pugh ME, Robbins IM, Rice TW, West J, Newman JH, Hemnes AR. Unrecognized glucose intolerance is common in pulmonary arterial hypertension. J Heart Lung Transplant. 2011;30:904-911. doi: 10.1016/j.healun.2011.02.016.
7. Xu W, Koeck T, Lara AR, Neumann D, DiFilippo FP, Koo M, Janocha AJ, Masri FA, Arroliga AC, Jennings C, Dweik RA, Tuder RM, Stuehr DJ, Erzurum SC. Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A. 2007;104:1342-1347. doi: 10.1073/pnas.0605080104.
8. Love DC, Hanover JA. The hexosamine signaling pathway: deciphering the "O-GlcNAc code". Sci STKE. 2005;2005:re13. doi: 10.1126/stke.3122005re13.
9. Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991;266:4706-4712.
10. Wells L, Vosseller K, Hart GW. A role for N-acetylglucosamine as a nutrient sensor and mediator of insulin resistance. Cell Mol Life Sci. 2003;60:222-228.
11. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, eds. Essentials of Glycobiology, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
12. Hart GW, Housley MP, Slawson C. Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature. 2007;446:1017-1022. doi: 10.1038/nature05815.
13. Hart GW, Slawson C, Ramirez-Correa G, Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. Annu Rev Biochem. 2011;80:825-858. doi: 10.1146/annurev-biochem-060608-102511.
14. Kreppel LK, Blomberg MA, Hart GW. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats. J Biol Chem. 1997;272:9308-9315.
15. Lubas WA, Frank DW, Krause M, Hanover JA. O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats. J Biol Chem. 1997;272:9316-9324.
16. Gao Y, Wells L, Comer FI, Parker GJ, Hart GW. Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J Biol Chem. 2001;276:9838-9845. doi: 10.1074/jbc.M010420200.
17. Wells L, Gao Y, Mahoney JA, Vosseller K, Chen C, Rosen A, Hart GW. Dynamic O-glycosylation of nuclear and cytosolic proteins: further characterization of the nucleocytoplasmic beta-N-acetylglucosaminidase, O-GlcNAcase. J Biol Chem. 2002;277:1755-1761.
18. Capotosti F, Guernier S, Lammers F, Waridel P, Cai Y, Jin J, Conaway JW, Conaway RC, Herr W. O-GlcNAc transferase catalyzes site-specific proteolysis of HCF-1. Cell. 2011;144:376-388. doi: 10.1016/j.cell.2010.12.030.
19. Lazarus MB, Jiang J, Kapuria V, Bhuiyan T, Janetzko J, Zandberg WF, Vocadlo DJ, Herr W, Walker S. HCF-1 is cleaved in the active site of O-GlcNAc transferase. Science. 2013;342:1235-1239. doi: 10.1126/science.1243990.
20. Lauer ME, Aytekin M, Comhair SA, Loftis J, Tian L, Farver CF, Hascall VC, Dweik RA. Modification of hyaluronan by heavy chains of inter-alpha-inhibitor in idiopathic pulmonary arterial hypertension. J Biol Chem. 2014;289:6791-6798. doi: 10.1074/jbc.M113.512491.
21. Comhair SA, Xu W, Mavrakis L, Aldred MA, Asosingh K, Erzurum SC. Human primary lung endothelial cells in culture. Am J Respir Cell Mol Biol. 2012;46:723-730. doi: 10.1165/rcmb.2011-0416TE.
22. Aytekin M, Comhair SA, de la Motte C, Bandyopadhyay SK, Farver CF, Hascall VC, Erzurum SC, Dweik RA. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2008;295:L789-L799. doi: 10.1152/ajplung.90306.2008.
23. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 suppl):D34-D41. doi: 10.1016/j.jacc.2013.10.029.
24. Park K, Saudek CD, Hart GW. Increased expression of beta-N-acetylglucosaminidase in erythrocytes from individuals with pre-diabetes and diabetes. Diabetes. 2010;59:1845-1850. doi: 10.2337/db09-1086.
25. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671-675.
26. Rehman J, Archer SL. A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the Warburg model of pulmonary arterial hypertension. Adv Exp Med Biol. 2010;661:171-185. doi: 10.1007/978-1-60761-500-2-11.
27. Lundgrin EL, Park MM, Sharp J, Tang WH, Thomas JD, Asosingh K, Comhair SA, DiFilippo FP, Neumann DR, Davis L, Graham BB, Tuder RM, Dostanic I, Erzurum SC. Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year. Ann Am Thorac Soc. 2013;10:1-9. doi: 10.1513/AnnalsATS.201206-029OC.
28. Rufino M, Hernández D, Barrios Y, Salido E. The GLUT-1 XbaI gene polymorphism is associated with vascular calcifications in nondiabetic uremic patients. Nephron Clin Pract. 2008;108:c182-c187. doi: 10.1159/000118940.
29. Kamigaito T, Okaneya T, Kawakubo M, Shimojo H, Nishizawa O, Nakayama J. Overexpression of O-GlcNAc by prostate cancer cells is significantly associated with poor prognosis of patients. Prostate Cancer Prostatic Dis. 2014;17:18-22. doi: 10.1038/pcan.2013.56.
30. Lynch TP, Ferrer CM, Jackson SR, Shahriari KS, Vosseller K, Reginato MJ. Critical role of O-Linked β-N-acetylglucosamine transferase in prostate cancer invasion, angiogenesis, and metastasis. J Biol Chem. 2012;287:11070-11081. doi: 10.1074/jbc.M111.302547.
31. Morrell NW, Archer SL, Defelice A, Evans S, Fiszman M, Martin T, Saulnier M, Rabinovitch M, Schermuly R, Stewart D, Truebel H, Walker G, Stenmark KR. Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension. Pulm Circ. 2013;3:226-244. doi: 10.4103/2045-8932.109940.
32. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
33. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441-464. doi: 10.1146/annurev-cellbio-092910-154237.
34. Diaz-Ruiz R, Rigoulet M, Devin A. The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim Biophys Acta. 2011;1807:568-576. doi: 10.1016/j.bbabio.2010.08.010.
35. Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-κB activity in pancreatic cancer cells. J Biol Chem. 2013;288:15121-15130. doi: 10.1074/jbc.M113.470047.
36. Taniguchi N. A sugar-coated switch for cellular growth and arrest. Nat Chem Biol. 2007;3:307-309. doi: 10.1038/nchembio0607-307.
37. Einstein FH, Fishman S, Bauman J, Thompson RF, Huffman DM, Atzmon G, Barzilai N, Muzumdar RH. Enhanced activation of a "nutrient-sensing"pathway with age contributes to insulin resistance. FASEB J. 2008;22:3450-3457. doi: 10.1096/fj.08-109041.
38. Wellen KE, Lu C, Mancuso A, Lemons JM, Ryczko M, Dennis JW, Rabinowitz JD, Coller HA, Thompson CB. The hexosamine biosynthetic pathway couples growth factor-induced glutamine uptake to glucose metabolism. Genes Dev. 2010;24:2784-2799. doi: 10.1101/gad.1985910.
39. Vaidyanathan K, Durning S, Wells L. Functional O-GlcNAc modifications: implications in molecular regulation and pathophysiology. Crit Rev Biochem Mol Biol. 2014;49:140-163. doi: 10.3109/10409238.2014.884535.
40. Chou TY, Dang CV, Hart GW. Glycosylation of the c-Myc transactivation domain. Proc Natl Acad Sci U S A. 1995;92:4417-4421.
41. Vosseller K, Wells L, Lane MD, Hart GW. Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes. Proc Natl Acad Sci U S A. 2002;99:5313-5318. doi: 10.1073/pnas.072072399.
42. Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD, Hart GW. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem. 2004;279:30133-30142. doi: 10.1074/jbc.M403773200.
43. Tyagi S, Chabes AL, Wysocka J, Herr W. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyl-transferases. Mol Cell. 2007;27:107-119. doi: 10.1016/j.molcel.2007.05.030.
44. Julien E, Herr W. Proteolytic processing is necessary to separate and ensure proper cell growth and cytokinesis functions of HCF-1. EMBO J. 2003;22:2360-2369. doi: 10.1093/emboj/cdg242.
45. Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart GW, Ripplinger CM, Bers DM. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013;502:372-376. doi: 10.1038/nature12537.
46. Jensen RV, Zachara NE, Nielsen PH, Kimose HH, Kristiansen SB, Bøtker HE. Impact of O-GlcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients. Cardiovasc Res. 2013;97:369-378. doi: 10.1093/cvr/cvs337.
47. McLarty JL, Marsh SA, Chatham JC. Post-translational protein modification by O-linked N-acetyl-glucosamine: its role in mediating the adverse effects of diabetes on the heart. Life Sci. 2013;92:621-627. doi: 10.1016/j.lfs.2012.08.006.
48. Issad T, Masson E, Pagesy P. O-GlcNAc modification, insulin signaling and diabetic complications. Diabetes Metab. 2010;36(6 pt 1):423-435. doi: 10.1016/j.diabet.2010.09.001.
49. Dentin R, Hedrick S, Xie J, Yates J 3rd, Montminy M. Hepatic glucose sensing via the CREB coactivator CRTC2. Science. 2008;319:1402-1405. doi: 10.1126/science.1151363.
50. Ball LE, Berkaw MN, Buse MG. Identification of the major site of O-linked beta-N-acetylglucosamine modification in the C terminus of insulin receptor substrate-1. Mol Cell Proteomics. 2006;5:313-323. doi: 10.1074/mcp.M500314-MCP200.
51. McClain DA, Lubas WA, Cooksey RC, Hazel M, Parker GJ, Love DC, Hanover JA. Altered glycan-dependent signaling induces insulin resistance and hyperleptinemia. Proc Natl Acad Sci U S A. 2002;99:10695-10699. doi: 10.1073/pnas.152346899.
52. Hanover JA, Krause MW, Love DC. The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine. Biochim Biophys Acta. 2010;1800:80-95. doi: 10.1016/j.bbagen.2009.07.017.
53. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM, Rabinovitch M, Doyle RL. Insulin resistance in pulmonary arterial hypertension. Eur Respir J. 2009;33:318-324. doi: 10.1183/09031936.00000508.
54. Brunner NW, Skhiri M, Fortenko O, Hsi A, Haddad F, Khazeni N, Zamanian RT. Impact of insulin resistance on ventricular function in pulmonary arterial hypertension. J Heart Lung Transplant. 2014;33:721-726. doi: 10.1016/j.healun.2014.02.016.
55. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L, Sheikh AY, Suen RS, Stewart DJ, Rabinovitch M. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation. 2007;115:1275-1284. doi: 10.1161/CIRCULATIONAHA.106.663120.